Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after ...

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) will likely be releasing its earnings data after the market closes ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.

Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is $0.52 (+2500.0% Y/Y) and the consensus ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...